3 doses, 21 hours

IV Acetadote is

  • FDA-Approved IV N-Acetylcysteine
  • The only EDTA-free N-Acetylcysteine formulation

IV Acetadote may be the right choice for:

  • Patients presenting with significant nausea and vomiting, a symptom of acetaminophen overdose
  • Patients who are unconscious
  • Patients who cannot tolerate oral medication

For maximal protection against hepatic injury administer IV Acetadote within 8 hours post-ingestion.


Patients with previous anaphylactoid reaction to acetylcysteine.


  • Serious acute hypersensitivity reactions including rash, hypotension, wheezing, and/or shortness of breath may occur soon after initiation of infusion
  • Use with caution in patients with asthma or history of bronchospasm
  • Immediately discontinue infusion if a serious reaction occurs and initiate appropriate treatment
  • Adjust total volume administered for patients less than 40 kg and for those requiring fluid restriction

About Acetaminophen Overdose

Based on data from the American Association of Poison Control Centers (AAPCC), acetaminophen was involved in more than 187,000 poisoning exposures in the United States in 2009, including more than 100,000 cases of acetaminophen in combination with other medications. About 46,000 exposures were treated in healthcare facilities.1 Of those treated approximately 26,000 received N-acetylcysteine.

About Acetadote

The only EDTA-free IV acetylcysteine formulation for acetaminophen overdose.

Acetadote, introduced in the United States in 2004 and currently used in more than 3,000 hospitals across the U.S., is a safe and efficacious treatment for acetaminophen overdose when administered within 8-10 hours post-ingestion. With a 3-dose, 21-hour IV N-acetylcysteine infusion, Acetadote is the shortest FDA-approved treatment regimen for acetaminophen overdose.


Acetadote is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion.


In the literature, the most frequently reported adverse reactions attributed to intravenous acetylcysteine administration were rash, urticaria and pruritus. The frequency of adverse reactions have been reported to be between 0.2% and 21%, and they most commonly occur during the initial loading dose of acetylcysteine.

View full Prescribing Information


  1. Bronstein AC, Spyker DA, Cantilena JR, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Tox 2010; 48:979-1178.